Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
221.3m USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
200.1B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
174.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
146.9B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
126.6B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.4B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.7B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
49.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Orchestra Biomed Holdings Inc
Glance View
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Orchestra Biomed Holdings Inc is 93%, which is below its 3-year median of 93.3%.
Over the last 3 years, Orchestra Biomed Holdings Inc’s Gross Margin has decreased from 950% to 93%. During this period, it reached a low of 91.9% on Mar 31, 2024 and a high of 950% on Sep 30, 2022.
